Table 12.
Therapeutic Agents for Hormonal Control
Hormonal Derangement | Medication | Dose per Day | Side Effects |
---|---|---|---|
Hypercortisolism | Mitotane | 2–12 g, to target level 14–20 mg/L | See Table 7, use mainly for adrenolytic effects |
Mifepristone | 300–1200 mg | Fatigue, nausea, headache, hypokalemia, arthralgia, vomiting, edema, and endometrial thickening | |
Metyrapone | 250–3000 mg | Hyperandrogenemia | |
Ketoconazole | 200–1200 mg | Nausea, vomiting, abdominal pain, hepatotoxicity | |
Etomidate | 0.02–0.03 mg/kg/h | Sedation (usually occurs at significantly higher doses) | |
Aminoglutethemidea | 250–1000 mg | Rash, nausea, vomiting, anorexia, sedation, lethargy | |
Mineralocorticoid excess | Spironolactone | 25–200 mg | Hyperkalemia, gynecomastia |
Eplerenone | 50–200 mg | Hyperkalemia | |
Hyperandrogenemia | Spironolactone | Hyperkalemia, gynecomastia | |
Estrogen excess | Aromatase inhibitors | Anastrazole 1 mg | Bone loss, nausea |
Letrozole 2.5 mg | |||
Exemestane 25 mg | |||
SERMs (tamoxifen, raloxifene) | Tamoxifen 20–40 mg, raloxifen 60 mg | Deep venous thrombosis |
Abbreviation: SERM, selective estrogen receptor modulator.
Not commonly available anymore.